New Drug Approvals

PENTASA (mesalamine) for oral administration is a controlled-release formulation of mesalamine, an amino-salicylate anti-inflammatory agent for gastrointestinal use. Chemically, mesalamine is 5-amino-2-hydroxybenzoic acid. It has a molecular weight of 153.14.

The structural formula is:

PENTASA (mesalamine) structural formula illustration

25 mar 2013
KYORIN Pharmaceutical has been marketing mesalazine drugs, PENTASA® Tablets
250mg, PENTASA ® Tablets 500mg and PENTASA ® Enema 1g in Japan while continuously engaging in the development for inflammatory bowel diseases (IBD), including Ulcerative colitis and Crohn’s disease.
The development of PENTASA® Suppositories 1g has just been successfully completed as a new formulation, which is convenient to patients, that meets therapeutic needs for Ulcerative colitis

View original post


New Drug Approvals

Istradefylline (KW-6002) is a selective antagonist at the A2A receptor. It has been found to be useful in the treatment of Parkinson’s disease.[1] Istradefylline reduces dyskinesia resulting from long-term treatment with classical antiparkinson drugs such as levodopa. Istradefylline is an analog of caffeine.



Peter A. LeWitt, MD, M. Guttman, James W. Tetrud, MD, Paul J. Tuite, MD, Akihisa Mori, PhD, Philip Chaikin, PharmD, MD, Neil M. Sussman, MD (2008). “Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces off time in Parkinson’s disease: A double-blind, randomized, multicenter clinical trial (6002-US-005)”. Annals of Neurology63 (3): 295–302. doi:10.1002/ana.21315. PMID 18306243.


TUE 26 MAR 2013

Kyowa Hakko Kirin, has received approval for NOURIAST tablets 20 mg (istradefylline), a novel antiparkinsonian agent, has been approved for manufacturing and marketing in Japan.
NOURIAST is a selective adenosine A2A receptor antagonist for Parkinson’s disease…

View original post 18 more words

New Drug Approvals


26 March 2013

Boehringer Ingelheim and Eli Lilly and Company today announced the European Medicines Agency (EMA) has accepted for review a marketing authorisation application (MAA) for the investigational sodium glucose cotransporter-2 (SGLT2) inhibitor, empagliflozin, for the treatment of Type 2 Diabetes (T2D) in adults. The acceptance of the MAA marks the beginning of the review process in the European Union for this potential oral diabetes treatment.


A New Drug Application (NDA) for empagliflozin was recently submitted to the Food and Drug Administration (FDA) in the United States for the treatment of Type 2 Diabetes mellitus (T2D) in adults.

Empagliflozin is part of a class of drugs being investigated for the reduction of blood glucose levels in adults with T2D. In clinical trials to date, SGLT2 inhibitors have been shown to reduce blood glucose by removing excess glucose independently of beta cell function and insulin resistance.

* Empagliflozin…

View original post 339 more words

New Drug Approvals


MAR 26 2013

MHLW JAPAN has approved  Nippon Shinyaku Co’s Regtect (acamprosate) for support maintenance of abstinence in patients with alcohol dependence.

Acamprosate, also known as N-acetyl homotaurine and by the brand name Campral, is a drug used for treating alcohol dependence.

Acamprosate is thought to stabilize the chemical balance in the brain that would otherwise be disrupted by alcoholism, possibly by antagonizing glutamatergic N-methyl-D-aspartate receptors and agonizing gamma-aminobutyric acid (GABA) type A receptors. Reports indicate that acamprosate only works with a combination of attending support groups and abstinence from alcohol.Certain serious side effects include diarrhea, allergic reactions, irregular heartbeats, and low or high blood pressure, while less serious side effects include headaches, insomnia, and impotence. Acamprosate should not be taken by people with kidney problems or allergies to the drug.

Campral is manufactured and marketed in the United States by Forest Laboratories…

View original post 29 more words

Ubisoft Singapore's Blog


Design Concept

Transforming the inclined wall into a gigantic chalkboard using a few coats of magnetic and chalkboard paint.


  • Use colored chalk to change the design on the wall whenever you want.
  • Wipes off cleanly with normal chalkboard eraser, damp cloth, etc
  • Easily present diagrams/ideas without going to a meeting room
  • Pin up pictures/concept art with magnets; no more fallen blu-tack stuck under your shoes

View original post

Singapore Specialist Associates' Blog

Dr Ng obtained his medical degree from National University of Singapore in 1994, and postgraduate surgical qualifications from Edinburgh and Glasgow in 1999 and 2000. He underwent Advanced Surgical Training in Urology in Singapore, and upon completion in the year 2004, was appointed Associate Consultant at the Dept of Urology, Tan Tock Seng Hospital. In the year 2005, he took up a fellowship programme in urologic oncology at the University of Western Ontario, Canada. He was appointed Consultant at the Dept of Urology, Tan Tock Seng Hospital in 2006.

He set up his own private practice In Mt Elizabeth Medical Centre and Novena Medical Centre in Apr 2010.

Dr Ng has extensive experience in minimally invasive urological procedures. His subspecialty interests include: surgery for urological cancers, laparoscopic (keyhole) surgery including robotic surgery and single port surgery, and treatment of prostate problems and overactive bladder.

His research interests include the epidemiology…

View original post 53 more words